Results 111 to 120 of about 7,224 (167)

Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment. [PDF]

J Gastroenterol Hepatol
Ogawa E, Kohjima M, Koyanagi T, Dohmen K, Ooho A, Kawano A, Furusyo N, Kajiwara E, Satoh T, Takahashi K, Azuma K, Sugimoto R, Ichiki Y, Senju T, Amagase H, Tanaka M, Nakamuta M, Nomura H, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.   +19 more
europepmc   +1 more source

Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure-Editorial on "Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B". [PDF]

Korean J Gastroenterol
Lee SK.
europepmc   +1 more source

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort. [PDF]

HIV Med
Pierone G, Brunet L, Fusco JS, Sension MG, Dunbar MS, Gruber J, Dieterich DT, Fusco GP.   +7 more
europepmc   +1 more source

Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies. [PDF]

Infect Dis Ther
Antinori A, Yokomaku Y, Elinav H, Pullukçu H, de Wet J, Antela A, Lu PL, Sabranski M, Kim YS, Bonnet F, den Hollander J, Jackson A, Choy CY, Cai W, Zhang F, Thorpe D, Marongiu A, Harrison R, Jarrett J, Boffito M.   +19 more
europepmc   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR. [PDF]

Infect Chemother
Kim YS, Choi JY, Park DW, Kim SW, Kim TH, Ryu J, Harrison R, Lee JA, Park F, Lee SH.   +9 more
europepmc   +1 more source

Efficacy and safety of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) versus efavirenz, lamivudine, and tenofovir disoproxil fumarate (EFV+3TC + TDF) in late-presenting people with HIV rapid initial antiretroviral therapy. [PDF]

BMC Infect Dis
Li Q, Li J, Gao C, Zhao Y, Zhu L, Xiao J, Zhang F.   +6 more
europepmc   +1 more source

Safety and Effectiveness of Biktarvy^® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea. [PDF]

Infect Chemother
Kim SW, Peters J, Lang MG, Lee JA, Cha J, Kim YS.   +5 more
europepmc   +1 more source

Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Hu X, Kong Y, Liu Y, Liu T, Ma A, Li Y, Zhang Y, Li J, Zhang L, Li G.   +9 more
europepmc   +1 more source

Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide. [PDF]

AIDS Res Ther
Mounzer K, Osterman MD, Brunet L, Hsu RK, Pierone G, Fusco JS, Prata Menezes N, Gruber J, Lim T, Dunbar M, Fusco GP.   +10 more
europepmc   +1 more source